


Achaogen
Investor Relations Department
7000 Shoreline Court,
3rd Floor
South San Francisco, CA 94080
United States

[Visit IR website](#) 
[Sign-up for email alerts](#) 

NASDAQ: AKAO


Last Trade:	13.48
Trade Time:	4:00 PM ET Oct 18, 2017
Change:	-0.09  (0.663%)
Day Range	13.35 - 13.82
52-Week Range	3.68 - 27.79
Volume	518,242

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. We are developing plazomicin, our lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae, or CRE. In 2013, the Centers for Disease Control and Prevention identified CRE as a “nightmare bacteria” and an immediate public health threat that requires “urgent a... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Oct 5, 2017*
[Achaogen IDWeek 2017 Presentations Feature Plazomicin's Unique Potential to Treat MDR Enterobacteriaceae](#)
- Sep 28, 2017*
[Achaogen Awarded up to \\$18 Million Contract by BARDA to Support Development of Orally-Administered Antibacterial Candidate C-Scape](#)
- Sep 27, 2017*
[Achaogen Announces Multiple Plazomicin Presentations at IDWeek 2017](#)
- Sep 26, 2017*
[Achaogen Announces New Employment Inducement Grants](#)
- Sep 18, 2017*
[Achaogen to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Mar 14, 2017*
[Annual Report \(10-K\)](#)
- Apr 26, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Aug 8, 2017*
[Quarterly Report \(10-Q\)](#)
- May 8, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 7, 2016*
[Quarterly Report \(10-Q\)](#)